CURC

About CURC

This author has not yet filled in any details.
So far CURC has created 190 blog entries.

Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer

Speaker: N. Shore, Myrtle Beach (US)   Event: 35th Annual EAU Congress - Virtual (EAU20V)   Click here to watch webcast.

By | July 20th, 2020|

Dr. Shore joins the Duke Global Health Institute Board of Advisors

Dr. Neal D. Shore has been invited to join the prestigious Duke Global Health Institute Board of Advisors The inaugural board of advisors for Duke Global Health Institute, founded in 2009, was composed of 14 visionary members who embraced Duke’s vision to build a world-class program that would lead its peers in the charge to [...]

By | June 11th, 2020|

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer

Presented by: Neal D. Shore, Paul F. Schellhammer, Ronald F. Tutrone, Neil F. Mariados, Stacey S. Harrelson Click here to read more.

By | June 4th, 2020|

Olaparib for Metastatic Castration-Resistant Prostate Cancer- Published in The NEW ENGLAND JOURNAL of MEDICINE

Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Przemyslaw Twardowski, M.D., et al. Click here to read more.

By | June 4th, 2020|

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer- Published in The NEW ENGLAND JOURNAL of MEDICINE

Neal D. Shore, M.D., Fred Saad, M.D., Michael S. Cookson, M.D., M.M.H.C., Daniel J. George, M.D., Daniel R. Saltzstein, M.D., Ronald Tutrone, M.D., Hideyuki Akaza, M.D., Alberto Bossi, M.D., David F. van Veenhuyzen, M.B., Ch.B., M.Pharm.Med., Bryan Selby, M.S., Xiaolin Fan, Ph.D., Vicky Kang, M.D., et al., for the HERO Study Investigators* Click here to [...]

By | June 4th, 2020|

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer- Published in The NEW ENGLAND JOURNAL of MEDICINE

Presented by: Cora N. Sternberg, M.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal D. Shore, M.D., Ugo De Giorgi, M.D., Ph.D., David F. Penson, M.D., M.P.H., Ubirajara Ferreira, M.D., Ph.D., Eleni Efstathiou, M.D., Ph.D., Katarzyna Madziarska, M.D., Ph.D., Michael P. Kolinsky, M.D., Daniel I. G. Cubero, M.D., Ph.D., Bettina Noerby, M.D., et al., for [...]

By | June 4th, 2020|

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Presented by: Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Przemyslaw Twardowski, M.D., et al. Click here to read more.

By | April 30th, 2020|

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)

Neal D. Shore, Daniel Saltzstein, Paul Sieber, Bryan Mehlhaff, Lawrence Gervasi, Jennifer Phillips, Yu-Ning Wong, Huiling Pei, Tracy McGowan Click here to read more.

By | November 27th, 2019|